Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising Oral Doses of BI 1323495 in Healthy Male Subjects (Single-blind, Partially Randomised, Placebo-controlled Parallel Group Design)
Phase of Trial: Phase I
Latest Information Update: 24 Jan 2019
Price : $35 *
At a glance
- Drugs BI 1323495 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 16 Jan 2019 Status changed from active, no longer recruiting to completed.
- 13 Nov 2018 Status changed from recruiting to active, no longer recruiting.
- 02 Aug 2018 Status changed from not yet recruiting to recruiting.